Molecular Partners AG American Depositary Shares (MOLN)

About MOLN

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloi…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

134

Website

www.molecularpartners.com/

Fundamentals

1-day range

$4.56$4.65

Market cap

$166.30M

P/E (trailing)

—

P/E (forward)

-27.43

EPS (trailing)

$-2.02

Dividend yield

—

Beta

0.36

Avg. volume

4.6K

Forecasts

5 analyst ratings

Molecular Partners AG American Depositary Shares Competitors

Chosen by industry and closest market cap.

• MOLN

  Molecular Partners AG American Depositary Shares

  $4.5

  ▼ 3.27%
  Market cap $166.30MP/E —
  $2.66$3.96
• TNYA

  Tenaya Therapeutics Inc. Common Stock

  $0.691

  ▼ 0.58%
  Market cap $158.19MP/E —
  $0.532$2.35
• LENZ

  LENZ Therapeutics Inc. Common Stock

  $5.12

  ▲ 6.34%
  Market cap $156.62MP/E —
  $4.54$50.4
• HUMA

  Humacyte Inc. Common Stock

  $0.6538

  ▼ 5.66%
  Market cap $153.04MP/E —
  $0.5261$2.55
• VYGR

  Voyager Therapeutics Inc. Common Stock

  $3.54

  ▲ 2.17%
  Market cap $181.26MP/E —
  $2.94$5.55
• CRBU

  Caribou Biosciences Inc. Common Stock

  $1.62

  ▼ 2.41%
  Market cap $148.77MP/E —
  $1.38$3.54
• ARMP

  Armata Pharmaceuticals Inc. Common Stock

  $5.24

  ▼ 3.50%
  Market cap $185.39MP/E —
  $2.4$16.34

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

3.59M

Total value held

$14.24M

Institutional holders

4